---
title: "Hong Kong health service provider Jikong Regeneration submitted an IPO application to the US stock market, aiming to raise USD 20 million"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/231174906.md"
description: "The Hong Kong-based pain management and health service provider Function Rebirth submitted an IPO application to the U.S. Securities and Exchange Commission (SEC) last Friday, planning to raise up to $20 million. The company plans to issue 5 million shares at a price of $4 per share, raising $20 million. At the proposed price, Function Rebirth's market capitalization will reach $220 million. Under its ANKH brand, Function Rebirth offers a wide range of non-surgical, non-invasive, and non-drug pain management treatments and therapies, functional enhancement therapies, and health products. The company provides pain management and functional enhancement services through three service centers in Hong Kong. Function Rebirth was founded in 2007, and its revenue for the 12 months ending September 30, 2024, was $41 million. The company confidentially submitted its listing application on June 21, 2024. D. Boral Capital is the sole bookrunner for the transaction"
datetime: "2025-03-10T07:35:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/231174906.md)
  - [en](https://longbridge.com/en/news/231174906.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/231174906.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/231174906.md) | [繁體中文](https://longbridge.com/zh-HK/news/231174906.md)


# Hong Kong health service provider Jikong Regeneration submitted an IPO application to the US stock market, aiming to raise USD 20 million

According to the Zhitong Finance APP, Hong Kong-based pain management and health service provider Functional Regeneration submitted an IPO application to the U.S. Securities and Exchange Commission (SEC) last Friday, planning to raise up to $20 million. The company plans to issue 5 million shares at a price of $4 per share, raising $20 million. At the proposed price, Functional Regeneration's market capitalization will reach $220 million.

Under its ANKH brand, Functional Regeneration offers a wide range of non-surgical, non-invasive, and non-drug pain management treatments and therapies, functional enhancement therapies, and health products. The company provides pain management and functional enhancement services through three service centers in Hong Kong.

Functional Regeneration was established in 2007, with revenue of $41 million for the 12 months ending September 30, 2024. The company submitted its listing application confidentially on June 21, 2024. D. Boral Capital is the sole bookrunner for the transaction

## 相关资讯与研究

- [14:01 ETCritical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale](https://longbridge.com/zh-CN/news/280673102.md)
- [Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call](https://longbridge.com/zh-CN/news/281187029.md)
- [AstraZeneca’s rare disease unit posts positive Phase III data for new hypophosphatasia therapy](https://longbridge.com/zh-CN/news/281133098.md)
- [Abitare In to Present Urban Regeneration Strategy at Euronext STAR Conference 2026](https://longbridge.com/zh-CN/news/280201629.md)
- [Fda issuance of a priority review voucher to the sponsor of a rare pediatric disease product application- federal register website](https://longbridge.com/zh-CN/news/281378968.md)